All the Active Ingredient Drugs
MMR Vaccine. Live attenuated measles virus 10^3.0 CCID50, Live attenuated mumps virus 10^3.7 CCID50, Live attenuated rubella virus 10^3.0 CCID50. VIALS (+ sterile diluent): 1 x 0.5 ml.
Single dose S.C.
Active immun. against measles, mumps.
rubella.
C/I: Hypersens. incl. to neomycin. A hist. of contact dermatitis to neomycin is not a contraindic. Current or recent immunosuppressive ther. (including high doses of corticosteroids). This drug is not contraindic. in pts. who are receiving topical or low-dose parenteral corticosteroids (e.g. for asthma prophylaxis or replacement ther.). Sev. humoral or cellular (primary or acquired) immunodefic., e.g. sev. combined immunodefic., agammaglobulinemia and AIDS or symptomatic HIV infect. or an age-specific CD4+ T-lymphocyte percent. in child. below 12 months: CD4+ <25 %; child. between 12-35 months: CD4+ < 20 %; child. between 36-59 months: CD4+ < 15 %.
MMRV Vaccine. Live attenuated measles virus NLT 10^ 3 CCID, Live attenuated mumps virus NLT 10^ 4.4 CCID, Live attenuated rubella virus NLT 10^ 3 CCID, Varicella virus live attenuated >=10 ^ 3.3 PFU. AMP. (Pwdr. + solv. for sol. for inj.): 1, 10,
20, 50×0.5ml. Infan., child. 12 mnths.
up to 12 yrs.: two doses (each of 0.5
ml). The interv. should prefer. btwn. 6
wks.- 3 mnths. When the 1st dose is admin. at 11 mnths. of age, the 2nd
dose should be admin. within 3 mnths.
Under no circumst. should the dose
interv. be less than 4 wks.
Active immunis. against measles,
mumps, rubella, varicella in child. 12
mnth. - 12 yrs. includ.
C/I: Pts. acute sev. febr. illness.
Hypersens. to act. subst. or to neomycin.
Previous episodes of hypersens. after
admin. of MMR and/or varicella vacc.
Current or recent immunosuppress. Ther
Severe humoral/ cellular (primary/
acquired) immunodefic., e.g. severe
combined immunodef.,
agammaglobulinemia, AIDS or sympt.
HIV infec. or an age-specific CD4+
T-lymphocyte percentage in child.
below 12 mnths.: CD4+ <25%; children
btwn. 12-35 mnths.: CD4+ < 20%; child.
btwn. 36-59 mnths.: CD4+ < 15%
Preg., preg. should be avoid. for 1m.
follow. vacc.
MMRV Vaccine. Live attenuated measles virus => 10^3 TCID, Live attenuated mumps virus => 10^4.3 TCID, Live attenuated rubella virus => 10^3 TCID, Varicella virus live attenuated => 10^3.99 PFU. Powder and Solvent for Susp. for IM or SC Inject. Vials X1/X10
Individuals 12 months of age to 12 years of age : should receive 2 doses of this prod. or a single dose of this prod. followed by a second dose of a monovalent varicella vaccine to ensure optimal protect. against varicella. At least 1 month must elapse between the first and second dose of any live viral attenuated vaccine. It is preferred that the second dose be admin. within 3 months after the first dose.
Individuals between 9 and 12 months of age: immunogenicity and safety data show that this prod. can be admin. to individuals between 9 and 12 months of age, under special circumstances (e.g., in accordance with official recommen. or when early protect. is considered necessary). In such cases, individuals should receive a second dose of this prod., given at a min. of 3 months apart, to ensure optimal protect. against measles and varicella
For simultaneous vaccinat. against measles, mumps, rubella, and varicella in
individuals from 12 months of age to 12 years of age.
This vacc. can be admin. to individuals from 9 months of age under special circumstances:outbreak situations, or travel to a region with high prevalence of measles
C/I: Hypersens., Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting haematopoietic and lymphatic system/Current immunosuppressive ther. (including high doses of corticosteroids). Not contraindic. in individuals who are receiving topical or low-dose parenteral corticosteroids (e.g. for asthma prophylaxis or replacement ther)/Severe humoral or cellular (primary or acquired) immunodeficiency, e.g., severe combined immunodeficiency, agammaglobulinemia and AIDS or symptomatic HIV infect. or an age-specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+<25% , children between 12-35 months: CD4+ <15%.
In severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infect. have been reported/Family hist. of congenital or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated. /Active untreated TB. Children under tmt for TB have not experienced exacerbation of the dis., when immunised with live measles virus vaccine. No studies have been reported to date on the effect of measles virus vaccines on children with untreated TB/ Vaccinat. should be postponed during any illness with fever >38.5°C/.Pregn. Furthermore, pregn. should be avoided for 1 month following vaccinat.
